Ind-Swift Laboratories Limited has informed the Exchange about Conversion

Warrants convertedFund Raising View source PDF Explain this filing

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹112.00

prior close

₹112.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+2.3% vs market

Pharmaceuticals peers, median of 151sector+0.2%+2.1% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.5

15m

+0.5

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3+0.1+2.3+0.2+2.1

Next day

+1.8+0.5+1.4+0.8+1.1

+7.2-0.0+7.2+0.2+7.0

+7.1-0.1+7.3+0.0+7.1

+4.0+0.4+3.7+0.1+4.0

-6.0+0.7-6.8-0.2-5.9

-4.7+0.4-5.0+0.3-4.9

15d

-6.3+1.1-7.3+0.5-6.7

-7.1-2.0-5.1-1.4-5.7

-8.5-1.9-6.6-2.8-5.7

-13.4-2.7-10.6-3.1-10.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ind-Swift Laboratories has allotted 65,82,876 equity shares (face value ₹10 each) upon conversion of an equal number of fully convertible warrants that were originally issued on August 30, 2024. The conversion price was ₹121 per share, and the company received a balance subscription amount of approximately ₹59.74 crore from this conversion. Allottees include promoter entity Essix Biosciences Limited (11,00,000 shares), and non-promoters HCP Investments (30,14,876 shares) and Zeal Global Opportunities Fund (24,68,000 shares). Following this allotment, the company's paid-up equity share capital has increased to ₹67.20 crore, divided into 6.72 crore equity shares of ₹10 each.

Likely market impact

This is a dilutive event for existing shareholders as the share count has expanded, though the company has strengthened its equity base by ~₹59.74 crore. Investors should note the expanded share base when evaluating per-share metrics going forward.